Immune checkpoint inhibitor‐induced diabetes mellitus: A case series from a large tertiary centre in the UK
Study context
- Population
- Adults with new-onset insulin-dependent immune checkpoint inhibitors (ICI)-induced DM (ICI-induced diabetes mellitus (ICI-DM)) after ICI treatment, 2017–2026, large tertiary centre, UK
- Participants
- 13 adults
- Outcome
- Clinical features of ICI-DM
Methodological detailssingle-centre, retrospective review of electronic medical records, Data extracted from electronic medical records (EPIC® Systems Corporation)
- Single-centre
- Retrospective review of electronic medical records
- Data extracted from electronic medical records (EPIC® Systems Corporation)
Main finding
As reported in the abstract
- Male
- 61.5%
- Age, median (IQR)
- 61 years (45-71)
- White ethnic background
- 84.6%
- Time from ICI start to ICI-DM presentation, median (IQR)
- 4 months (2-18)
- Presented with diabetic ketoacidosis (DKA)
- n = 9, 69.2%
- DKA requiring intensive care
- 2
- DKA potentially avoidable with earlier insulin initiation
- 3
- Diabetes autoantibodies positive
- 54.5%
- GAD65 antibodies
- 5
- IA-2 antibodies
- 1
- C-peptide at diagnosis, median (IQR)
- 161 pmol/L (10-232)
- HbA1c before ICI start, mean ± SD
- 40 ± 7 mmol/mol (5.8 ± 2.8%)
- HbA1c at diagnosis, mean ± SD
- 80 ± 15 mmol/mol (9.5 ± 3.5%)
- Interval from pre-ICI HbA1c to diagnosis, median (IQR)
- 3 months (2-4)
Observational data: associations, not effects.
Original publication
Immune checkpoint inhibitor‐induced diabetes mellitus: A case series from a large tertiary centre in the UK. Diabet Med. Published 28 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →